Printer Friendly

Gilead and Tibotec team up.

FOSTER CITY, Calif. -- Gilead Sciences Inc. has entered into a license and collaboration agreement with Tibotec Pharmaceuticals for the development and commercialization of a once-daily, fixed-dose antiretroviral regimen containing Gilead's Truvada (emtricitabine and tenofovir disoproxil fumarate) and Tibotec's investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 (rilpivirine hydrochloride, 25 mg) for treatment-naive HIV-infected individuals.

Fixed-dose combinations contain multiple medicines formulated into one tablet and help simplify HIV therapy.

"Gilead and Tibotec share a strong focus on bringing safe and effective treatment options to people living with HIV/AIDS," says John Martin, chairman and chief executive officer of Gilead Sciences. "Fixed-dose regimens have become the standard of care as HIV treatment has evolved toward more simplified regimens for patients. We look forward to advancing this new fixed-dose product."

Subject to regulatory approval, Gilead will assume the lead role in the manufacturing, registration, distribution and commercialization of the fixed-dose combination of Truvada and rilpivirine worldwide (excluding the developing world and Japan.) Tibotec will be responsible for the commercialization of rilpivirine as a stand-alone product and will hold rights to co-promote the fixed-dose combination in these areas.

The companies said they will also work toward an agreement to make the fixed-dose combination of Truvada and rilpivirine available in the developing world.

COPYRIGHT 2009 Racher Press, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:RX RETAIL PHARMACY: Biotechnology
Publication:Chain Drug Review
Article Type:Brief article
Date:Aug 3, 2009
Previous Article:Ilaris takes big step forward in European Union.
Next Article:CE catalog highlights.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |